Carregant...
The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma
SIMPLE SUMMARY: Multiple myeloma is the second most common cancer of the blood system in the US. Despite new therapies, a cure remains elusive, and current drugs inevitably become ineffective due to various resistance mechanisms. A frontline clinical strategy is the inhibition of the proteasome, the...
Guardat en:
| Publicat a: | Cancers (Basel) |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7922145/ https://ncbi.nlm.nih.gov/pubmed/33671345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13040843 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|